47.41 USD
+0.49 (+1.04%)
Last: Feb 6, 2026, 02:04 PM
COLL gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. While COLL has a great profitability rating, there are some minor concerns on its financial health. COLL may be a bit undervalued, certainly considering the very reasonable score on growth These ratings could make COLL a good candidate for value investing.
1. Profitability
1.1 Basic Checks
- In the past year COLL was profitable.
- COLL had a positive operating cash flow in the past year.
- Of the past 5 years COLL 4 years were profitable.
- COLL had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- COLL has a better Return On Assets (3.64%) than 83.77% of its industry peers.
- COLL has a Return On Equity of 21.27%. This is amongst the best in the industry. COLL outperforms 91.10% of its industry peers.
- COLL's Return On Invested Capital of 9.10% is amongst the best of the industry. COLL outperforms 87.96% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for COLL is in line with the industry average of 12.87%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.64% | ||
| ROE | 21.27% | ||
| ROIC | 9.1% |
ROA(3y)2.08%
ROA(5y)4.15%
ROE(3y)14.01%
ROE(5y)18.34%
ROIC(3y)11.08%
ROIC(5y)9.32%
1.3 Margins
- COLL's Profit Margin of 7.72% is amongst the best of the industry. COLL outperforms 82.20% of its industry peers.
- In the last couple of years the Profit Margin of COLL has declined.
- COLL has a better Operating Margin (20.74%) than 89.01% of its industry peers.
- COLL's Operating Margin has improved in the last couple of years.
- COLL has a Gross Margin of 57.22%. This is in the better half of the industry: COLL outperforms 68.59% of its industry peers.
- In the last couple of years the Gross Margin of COLL has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.74% | ||
| PM (TTM) | 7.72% | ||
| GM | 57.22% |
OM growth 3Y43.71%
OM growth 5YN/A
PM growth 3Y-24.85%
PM growth 5YN/A
GM growth 3Y3.19%
GM growth 5Y11.47%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), COLL is creating some value.
- Compared to 1 year ago, COLL has less shares outstanding
- The number of shares outstanding for COLL has been reduced compared to 5 years ago.
- Compared to 1 year ago, COLL has an improved debt to assets ratio.
2.2 Solvency
- Based on the Altman-Z score of 1.48, we must say that COLL is in the distress zone and has some risk of bankruptcy.
- COLL has a Altman-Z score (1.48) which is comparable to the rest of the industry.
- COLL has a debt to FCF ratio of 2.79. This is a good value and a sign of high solvency as COLL would need 2.79 years to pay back of all of its debts.
- Looking at the Debt to FCF ratio, with a value of 2.79, COLL belongs to the top of the industry, outperforming 91.62% of the companies in the same industry.
- COLL has a Debt/Equity ratio of 2.71. This is a high value indicating a heavy dependency on external financing.
- The Debt to Equity ratio of COLL (2.71) is worse than 80.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.71 | ||
| Debt/FCF | 2.79 | ||
| Altman-Z | 1.48 |
ROIC/WACC0.97
WACC9.35%
2.3 Liquidity
- COLL has a Current Ratio of 1.36. This is a normal value and indicates that COLL is financially healthy and should not expect problems in meeting its short term obligations.
- With a Current ratio value of 1.36, COLL is not doing good in the industry: 73.82% of the companies in the same industry are doing better.
- COLL has a Quick Ratio of 1.27. This is a normal value and indicates that COLL is financially healthy and should not expect problems in meeting its short term obligations.
- The Quick ratio of COLL (1.27) is worse than 70.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.36 | ||
| Quick Ratio | 1.27 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 30.73% over the past year.
- The Earnings Per Share has been growing by 154.78% on average over the past years. This is a very strong growth
- The Revenue has grown by 26.34% in the past year. This is a very strong growth!
- COLL shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.31% yearly.
EPS 1Y (TTM)30.73%
EPS 3Y154.78%
EPS 5YN/A
EPS Q2Q%39.75%
Revenue 1Y (TTM)26.34%
Revenue growth 3Y31.63%
Revenue growth 5Y16.31%
Sales Q2Q%31.42%
3.2 Future
- COLL is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -1.58% yearly.
- The Revenue is expected to grow by 3.62% on average over the next years.
EPS Next Y18.1%
EPS Next 2Y12.32%
EPS Next 3Y-0.6%
EPS Next 5Y-1.58%
Revenue Next Year24.13%
Revenue Next 2Y13.42%
Revenue Next 3Y4.47%
Revenue Next 5Y3.62%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 6.59, the valuation of COLL can be described as very cheap.
- Based on the Price/Earnings ratio, COLL is valued cheaper than 93.72% of the companies in the same industry.
- When comparing the Price/Earnings ratio of COLL to the average of the S&P500 Index (27.67), we can say COLL is valued rather cheaply.
- A Price/Forward Earnings ratio of 5.83 indicates a rather cheap valuation of COLL.
- Based on the Price/Forward Earnings ratio, COLL is valued cheaply inside the industry as 93.72% of the companies are valued more expensively.
- COLL's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.20.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.59 | ||
| Fwd PE | 5.83 |
4.2 Price Multiples
- COLL's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. COLL is cheaper than 97.91% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, COLL is valued cheaper than 96.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.18 | ||
| EV/EBITDA | 4.88 |
4.3 Compensation for Growth
- COLL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- COLL has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)0.36
PEG (5Y)N/A
EPS Next 2Y12.32%
EPS Next 3Y-0.6%
5. Dividend
5.1 Amount
- COLL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:COLL (2/6/2026, 2:04:13 PM)
47.41
+0.49 (+1.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)02-19 2026-02-19/amc
Inst Owners120.33%
Inst Owner Change0.44%
Ins Owners1.42%
Ins Owner Change-0.82%
Market Cap1.50B
Revenue(TTM)757.07M
Net Income(TTM)58.44M
Analysts81.67
Price Target54.23 (14.39%)
Short Float %17.98%
Short Ratio10.87
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.9%
Min EPS beat(2)1.88%
Max EPS beat(2)7.92%
EPS beat(4)4
Avg EPS beat(4)6.15%
Min EPS beat(4)1.88%
Max EPS beat(4)12.85%
EPS beat(8)7
Avg EPS beat(8)12.99%
EPS beat(12)9
Avg EPS beat(12)-15.06%
EPS beat(16)10
Avg EPS beat(16)-21.97%
Revenue beat(2)2
Avg Revenue beat(2)5.22%
Min Revenue beat(2)1.9%
Max Revenue beat(2)8.53%
Revenue beat(4)3
Avg Revenue beat(4)2.75%
Min Revenue beat(4)-0.79%
Max Revenue beat(4)8.53%
Revenue beat(8)4
Avg Revenue beat(8)0.8%
Revenue beat(12)6
Avg Revenue beat(12)0.28%
Revenue beat(16)8
Avg Revenue beat(16)-3.75%
PT rev (1m)9.25%
PT rev (3m)19.21%
EPS NQ rev (1m)-3.66%
EPS NQ rev (3m)3.56%
EPS NY rev (1m)-0.9%
EPS NY rev (3m)-16.04%
Revenue NQ rev (1m)-0.44%
Revenue NQ rev (3m)5.33%
Revenue NY rev (1m)-0.14%
Revenue NY rev (3m)4.02%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.59 | ||
| Fwd PE | 5.83 | ||
| P/S | 1.98 | ||
| P/FCF | 5.18 | ||
| P/OCF | 5.15 | ||
| P/B | 5.45 | ||
| P/tB | N/A | ||
| EV/EBITDA | 4.88 |
EPS(TTM)7.19
EY15.17%
EPS(NY)8.14
Fwd EY17.16%
FCF(TTM)9.15
FCFY19.3%
OCF(TTM)9.2
OCFY19.41%
SpS23.95
BVpS8.69
TBVpS-18.86
PEG (NY)0.36
PEG (5Y)N/A
Graham Number37.5
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.64% | ||
| ROE | 21.27% | ||
| ROCE | 13.6% | ||
| ROIC | 9.1% | ||
| ROICexc | 12.09% | ||
| ROICexgc | N/A | ||
| OM | 20.74% | ||
| PM (TTM) | 7.72% | ||
| GM | 57.22% | ||
| FCFM | 38.21% |
ROA(3y)2.08%
ROA(5y)4.15%
ROE(3y)14.01%
ROE(5y)18.34%
ROIC(3y)11.08%
ROIC(5y)9.32%
ROICexc(3y)16.99%
ROICexc(5y)14.94%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)16.56%
ROCE(5y)13.94%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y15.58%
ROICexc growth 5YN/A
OM growth 3Y43.71%
OM growth 5YN/A
PM growth 3Y-24.85%
PM growth 5YN/A
GM growth 3Y3.19%
GM growth 5Y11.47%
F-Score7
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.71 | ||
| Debt/FCF | 2.79 | ||
| Debt/EBITDA | 1.94 | ||
| Cap/Depr | 0.72% | ||
| Cap/Sales | 0.21% | ||
| Interest Coverage | 2.17 | ||
| Cash Conversion | 75.92% | ||
| Profit Quality | 495.01% | ||
| Current Ratio | 1.36 | ||
| Quick Ratio | 1.27 | ||
| Altman-Z | 1.48 |
F-Score7
WACC9.35%
ROIC/WACC0.97
Cap/Depr(3y)142.93%
Cap/Depr(5y)207.67%
Cap/Sales(3y)41.34%
Cap/Sales(5y)49.06%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.73%
EPS 3Y154.78%
EPS 5YN/A
EPS Q2Q%39.75%
EPS Next Y18.1%
EPS Next 2Y12.32%
EPS Next 3Y-0.6%
EPS Next 5Y-1.58%
Revenue 1Y (TTM)26.34%
Revenue growth 3Y31.63%
Revenue growth 5Y16.31%
Sales Q2Q%31.42%
Revenue Next Year24.13%
Revenue Next 2Y13.42%
Revenue Next 3Y4.47%
Revenue Next 5Y3.62%
EBIT growth 1Y-18.86%
EBIT growth 3Y89.16%
EBIT growth 5YN/A
EBIT Next Year157.27%
EBIT Next 3Y28.14%
EBIT Next 5Y18.85%
FCF growth 1Y8.55%
FCF growth 3Y25.98%
FCF growth 5Y56.88%
OCF growth 1Y8.67%
OCF growth 3Y25.54%
OCF growth 5Y49.12%
COLLEGIUM PHARMACEUTICAL INC / COLL FAQ
What is the ChartMill fundamental rating of COLLEGIUM PHARMACEUTICAL INC (COLL) stock?
ChartMill assigns a fundamental rating of 6 / 10 to COLL.
What is the valuation status for COLL stock?
ChartMill assigns a valuation rating of 9 / 10 to COLLEGIUM PHARMACEUTICAL INC (COLL). This can be considered as Undervalued.
What is the profitability of COLL stock?
COLLEGIUM PHARMACEUTICAL INC (COLL) has a profitability rating of 8 / 10.
Can you provide the financial health for COLL stock?
The financial health rating of COLLEGIUM PHARMACEUTICAL INC (COLL) is 5 / 10.